Phase II Study With ITF2984 in Acromegalic Patients

NCT02111044 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Acromegaly

Interventions

DRUG: Octreotide
DRUG: ITF2984 500 mcg
DRUG: ITF2984 1000 mcg
DRUG: ITF2984 2000 mcg

Sponsor

Italfarmaco